The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

Multiple myeloma (MM) is a tumor of plasmablasts/plasma cells (PCs) characterized by the expansion of malignant PCs with complex genetic aberrations in the bone marrow (BM). Recent reports, by us and others, have highlighted the polycomb group (PcG) proteins as potential targets for therapy in MM. T...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Alzrigat, Mohammad, Párraga, Alba Atienza, Majumder, Muntasir Mamun, Ma, Anqi, Jin, Jian, Österborg, Anders, Nahi, Hareth, Nilsson, Kenneth, Heckman, Caroline A., Öberg, Fredrik, Kalushkova, Antonia, Jernberg-Wiklund, Helena
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732762/
https://ncbi.nlm.nih.gov/pubmed/29262596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21909
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items